BACKGROUND: Presensitized patients with circulating donor-specific antibodies (DSAs) before transplantation are at risk for antibody-mediated rejection (AMR). Peritransplant desensitization mitigates but does not eliminate the alloimmune response. We examined the possibility that subthreshold AMR activity undetected by histology could be operating in some early biopsies. METHODS: Transcriptome of kidney allograft biopsies performed within the first month in presensitized patients (DSA+) who had received desensitization and did not develop active/probable AMR by histology (R-) was compared with biopsies showing active/probable AMR (R+/DSA+). As negative controls, biopsies without rejection by histology in patients without DSA at transplantation were used (R-/DSA-). RNA sequencing from biopsies selected from the biobank was used in cohort 1 (n = 32) and microarray, including the molecular microscope (Molecular Microscope Diagnostic System [MMDx]) algorithm, in recent cohort 2 (n = 30). RESULTS: The transcriptome of R-/DSA+ was similar to R+/DSA+ as these groups differed in 14 transcripts only. Contrarily, large differences were found between both DSA+ groups and negative controls. Fast gene set enrichment analyses showed upregulation of the immune system in both DSA+ groups (gene ontology terms: adaptive immune response, humoral immune response, antigen receptor-mediated signaling, and B-cell receptor signaling or complement activation) when compared with negative controls. MMDx assessment in cohort 2 classified 50% of R-/DSA+ samples as AMR and found no differences in AMR molecular scores between R+ and R- DSA+ groups. In imlifidase desensitization, MMDx series showed a gradual increase in AMR scores over time. CONCLUSIONS: Presensitized kidney transplant recipients exhibited frequent molecular calls of AMR in biopsy-based transcript diagnostics despite desensitization therapy and negative histology.

Alberta Transplant Applied Genomics Centre Edmonton AB Canada

Department of Clinical and Transplant Pathology Institute for Clinical and Experimental Medicine Prague Czech Republic

Department of Computer Science Czech Technical University Prague Czech Republic

Department of Immunogenetics Institute for Clinical and Experimental Medicine Prague Czech Republic

Department of Medicine University of Alberta Edmonton AB Canada

Department of Nephrology Institute for Clinical and Experimental Medicine Prague Czech Republic

Transplant Laboratory Institute for Clinical and Experimental Medicine Prague Czech Republic

Zobrazit více v PubMed

Mohan S, Palanisamy A, Tsapepas D, et al. . Donor-specific antibodies adversely affect kidney allograft outcomes. J Am Soc Nephrol. 2012;23:2061–2071. PubMed PMC

Loupy A, Lefaucheur C. Antibody-mediated rejection of solid-organ allografts. N Engl J Med. 2018;379:1150–1160. PubMed

Schinstock CA, Mannon RB, Budde K, et al. . Recommended treatment for antibody-mediated rejection after kidney transplantation: the 2019 Expert Consensus From the Transplantation Society Working Group. Transplantation. 2020;104:911–922. PubMed PMC

Loupy A, Suberbielle-Boissel C, Hill GS, et al. . Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am J Transplant. 2009;9:2561–2570. PubMed

Madill-Thomsen KS, Bohmig GA, Bromberg J, et al. ; INTERCOMEX Investigators. Donor-specific antibody is associated with increased expression of rejection transcripts in renal transplant biopsies classified as no rejection. J Am Soc Nephrol. 2021;32:2743–2758. PubMed PMC

Haas M, Sis B, Racusen LC, et al. ; Banff Meeting Report Writing Committee. Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant. 2014;14:272–283. PubMed

Halloran PF, Madill-Thomsen KS, Pon S, et al. ; INTERCOMEX Investigators. Molecular diagnosis of ABMR with or without donor-specific antibody in kidney transplant biopsies: differences in timing and intensity but similar mechanisms and outcomes. Am J Transplant. 2022;22:1976–1991. PubMed PMC

Hruba P, Krejcik Z, Stranecky V, et al. . Molecular patterns discriminate accommodation and subclinical antibody-mediated rejection in kidney transplantation. Transplantation. 2019;103:909–917. PubMed

Jordan SC, Legendre C, Desai NM, et al. . Imlifidase desensitization in crossmatch-positive, highly sensitized kidney transplant recipients: results of an international phase 2 trial (Highdes). Transplantation. 2021;105:1808–1817. PubMed PMC

Kjellman C, Maldonado AQ, Sjoholm K, et al. . Outcomes at 3 years posttransplant in imlifidase-desensitized kidney transplant patients. Am J Transplant. 2021;21:3907–3918. PubMed PMC

Viklicky O, Hruba P, Novotny M, et al. . Targeting CD38 in subclinical antibody-mediated rejection in HLA-incompatible kidney transplantation: a case report. Transplant Direct. 2024;10:e1685. PubMed PMC

Mayer KA, Schrezenmeier E, Diebold M, et al. . A randomized phase 2 trial of felzartamab in antibody-mediated rejection. N Engl J Med. 2024;391:122–132. PubMed

Naesens M, Roufosse C, Haas M, et al. . The Banff 2022 Kidney Meeting Report: reappraisal of microvascular inflammation and the role of biopsy-based transcript diagnostics. Am J Transplant. 2024;24:338–349 PubMed

Conway JR, Lex A, Gehlenborg N. UpSetR: an R package for the visualization of intersecting sets and their properties. Bioinformatics. 2017;33:2938–2940. PubMed PMC

Halloran PF, Reeve J, Akalin E, et al. . Real time central assessment of kidney transplant indication biopsies by microarrays: the INTERCOMEX study. Am J Transplant. 2017;17:2851–2862. PubMed

Ritchie ME, Phipson B, Wu D, et al. . limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47. PubMed PMC

Blighe K, Rana S, Lewis M. EnhancedVolcano: publication-ready volcano plots with enhanced colouring and labeling. R package version 1220. 2024;doi:10.18129/B9.bioc

Reeve J, Bohmig GA, Eskandary F, et al. ; MMDx-Kidney Study Group. Assessing rejection-related disease in kidney transplant biopsies based on archetypal analysis of molecular phenotypes. JCI Insight. 2017;2:e94197. PubMed PMC

Kannabhiran D, Lee J, Schwartz JE, et al. . Characteristics of circulating donor human leukocyte antigen-specific immunoglobulin G antibodies predictive of acute antibody-mediated rejection and kidney allograft failure. Transplantation. 2015;99:1156–1164. PubMed PMC

Bromberg JS, Bunnapradist S, Samaniego-Picota M, et al. . Elevation of donor-derived cell-free DNA before biopsy-proven rejection in kidney transplant. Transplantation. 2024;108:1994–2004. PubMed PMC

Bu L, Gupta G, Pai A, et al. . Clinical outcomes from the assessing donor-derived cell-free DNA monitoring insights of kidney allografts with longitudinal surveillance (ADMIRAL) study. Kidney Int. 2022;101:793–803. PubMed

Zhao S, Fung-Leung WP, Bittner A, et al. . Comparison of RNA-Seq and microarray in transcriptome profiling of activated T cells. PLoS One. 2014;9:e78644. PubMed PMC

Halloran PF, Madill-Thomsen KS, Reeve J. The molecular phenotype of kidney transplants: insights from the MMDx project. Transplantation. 2024;108:45–71. PubMed PMC

Osickova K, Hruba P, Kabrtova K, et al. . Predictive potential of flow cytometry crossmatching in deceased donor kidney transplant recipients subjected to peritransplant desensitization. Front Med (Lausanne). 2021;8:780636. PubMed PMC

Lefaucheur C, Loupy A, Hill GS, et al. . Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol. 2010;21:1398–1406. PubMed PMC

Frischknecht L, Deng Y, Wehmeier C, et al. ; Swiss Transplant Cohort Study. The impact of pre-transplant donor specific antibodies on the outcome of kidney transplantation—data from the Swiss transplant cohort study. Front Immunol. 2022;13:1005790. PubMed PMC

Dominy KM, Willicombe M, Al Johani T, et al. . Molecular assessment of C4d-positive renal transplant biopsies without evidence of rejection. Kidney Int Rep. 2019;4:148–158. PubMed PMC

Hayde N, Broin PO, Bao Y, et al. . Increased intragraft rejection-associated gene transcripts in patients with donor-specific antibodies and normal biopsies. Kidney Int. 2014;86:600–609. PubMed

Halloran PF, Reeve J, Madill-Thomsen KS, et al. ; Trifecta Investigators. The Trifecta study: comparing plasma levels of donor-derived cell-free DNA with the molecular phenotype of kidney transplant biopsies. J Am Soc Nephrol. 2022;33:387–400. PubMed PMC